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Abstract. Drug reprofiling is emerging as an effective paradigm for discovery of 
cancer treatments. Herein, an antipsychotic drug is immobilised using the Magic 
Tag® chemical genomics tool and screened against a T7 bacteriophage displayed 
library of polypeptides from Drosophila melanogaster, as a whole genome model, to 
uncover an interaction with a section of 17--HSD10, a proposed prostate cancer 
target. A computational study and enzyme inhibition assay with full length human 17-
-HSD10 identifies risperidone as a drug reprofiling candidate. When formulated 
with rumenic acid, risperidone slows proliferation of PC3 prostate cancer cells in vitro 
and retards PC3 prostate cancer tumour growth in vivo in xenografts in mice, 
presenting an opportunity to reprofile risperidone as a cancer treatment. 
 
 
Highlights. The highly novel aspects of our program include: 
• demonstration that our recently developed Magic Tag® chemical genomics 
platform can be used to “reprofile” drugs into cancer indications; 
• the use of fruit fly Drosophila melanogaster as an unusual model organism for cancer 
drug discovery; 
• the further exploration of 17--hydroxysteroid dehydrogenase 10 as an emerging 
cancer target; 
• the potential of VAL401 as a candidate for clinical trials in adenocarcinomas. 
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1. Introduction 
In the search for new cancer treatments, the potential of existing drugs that have been 
or are being used for non-cancer indications remains under-investigated [1]. Drug 
reprofiling, (or repurposing or repositioning), is a commercially attractive route to 
new therapies, since it reduces risks in the development process by exploiting the 
well-known safety and pharmacokinetic profiles of the drugs [2]. In oncology, 
reprofiling successes include thalidomide (anti-emetic to multiple myeloma) and 
zoledronic acid (anti-bone resorption to multiple myeloma, prostate cancer and 
breast cancer) [3]. 
Very recently, systematic experimental [4] and in silico [5] approaches to reprofiling 
for oncology have emerged. Our Magic Tag® chemical genomics tool was designed to 
link the known biological activity of an organic chemical with the genome as 
expressed through a phage displayed library of polypeptides [6,7]. Herein we 
demonstrate that Magic Tag® has the potential to be a new and complementary 
method for systematically screening known drugs to identify reprofiling 
opportunities. Specifically, we present the widely used antipsychotic therapy 
risperidone as a possible treatment for prostate cancer and other adenocarcinomas. 
 Figure 1. Chemical structures of chlorpromazine 1, clozapine 2, risperidone 3 and clomipramine 4, 
with the common pharmacophore highlighted in red. 
 
Antipsychotic drugs such as chlorpromazine 1, clozapine 2 and risperidone 3 have 
long been known to display polypharmacology [8].  Known to have multiple protein 
targets, such drugs are interesting candidates for drug reprofiling. We decided to 
photoimmobilise one drug from this class, chlorpromazine 1, using Magic Tag® and 
screen it against a library of polypeptides displayed on T7 bacteriophage, as 
previously described [7].   
 
For drug reprofiling, a whole genome model is needed; we elected, as in our previous 
study of flecainide acetate, to use a display library originating from Drosophila 
melanogaster [9]. Despite its central importance to developments in both genetics 
and genomics, the common fruit fly, D. melanogaster, is underexploited in the field of 
drug discovery [10, 11]. Around 60% of D. melanogaster genes have human orthologs 
[12]. Significantly, around three quarters of genes related to human disease states 
have orthologs in D. melanogaster [7] and all major human signaling pathways are 
present in D. melanogaster [10]. 
 
2. Materials and Methods 
The Magic Tag® screen and enzyme kinetics studies used published methods [7, 13, 
14]. For other experiments chemicals, drugs and cell line media were acquired from 
Sigma Aldrich, Cell lines were acquired from ECACC or ATCC. The CytoTox 96 Non-
radioactive cytotoxicity assay (LDH Assay) was acquired from Promega (G1780). 
Preparation of drug treatments for cell line experiments. Stocks of rumenic acid 
were prepared at 100mM and risperidone at 10 mM in ethanol, aliquotted for 
storage.  For use, stocks were thawed at room temperature for 15 mins then 
dissolved 1:10 into F12K media containing 125µM fatty acid-free BSA, mixed by 
gentle vortexing and observations made. Where necessary preparations were 
placed in water bath at 37 °C to aid solubility. 
For preparation of VAL401 for testing in vitro, rumenic acid stocks were first 
prepared in fatty acid free BSA-F12K media, with serial dilution to a final “working” 
concentration of 100µM, vortexed gently to mix and incubated at 37 °C for 1 hour.  
Risperidone was added to the fatty acid BSA-media to the appropriate 
concentrations before addition to the cells.  Negative control wells were generated 
by the treatment of cells with media containing an equivalent concentration of 
ethanol; and positive control wells were generated by the use of wells containing 
media and treatment, but no cell monolayer. 
PC3 lysed cell LDH Assay. PC3 cells were seeded at a density of 4000 cells per well 
in a 96 well plate, and incubated at 37 °C, 5% CO2 for 48 hours in standard growth 
media (F12K nutrient mix + 7% fetal calf serum + 2 mM L-glutamine + 45 mg/L 
ascorbic acid).  The media was then removed by pipette and replaced with the 
appropriate drug treatment in treatment media (F12K nutrient mix + 125 M fatty 
acid free BSA + 2 mM L-glutamine + 45 mg/L ascorbic acid), and incubated for a 
further 96 hours at 37 °C, 5% CO2. 
The supernatant was removed from all wells of cells, and cells washed with 200 l 
PBS.  After removal of the PBS, the cells were lysed with 0.9% Triton-X in PBS for 2 
hours at 37 °C, 5% CO2.  50 l of this cell lysate was transferred to a fresh 96 well 
plate, 50 l of CytoTox 96 assay reagent was added and the plate incubated at room 
temperature in the dark for 20 minutes.  50 l stop reagent was then added and the 
optical absorbance at 492 nm was recorded. 
The percentage cell count was counted by normalising the untreated wells of cells as 
100% growth, and wells containing no cells normalised to 0%.  The mean and 
standard error of the replicate wells was calculated. 
Mouse xenograft experiments. Male MF-1 nude mice were obtained from the 
commercial suppliers (Harlan, UK) and were at least 7 weeks of age before being 
recruited to the study.  Mice were maintained in sterile isolators within a barriered 
unit illuminated by fluorescent lights set to give a 12 hour light-dark cycle (on 07.00, 
off 19.00), as recommended in the United Kingdom Home Office Animals (Scientific 
Procedures) Act 1986. The room was air-conditioned by a system designed to 
maintain an air temperature range of 21 ± 22 °C. Mice were from the same litter and 
housed in social groups of 4 during the procedure in plastic cages (Techniplast UK) 
with irradiated bedding and provided with both nesting materials and 
environmental enrichment.  Sterile irradiated 2019 rodent diet (Harlan Teckland 
UK, product code Q219DJ1R2) and autoclaved water were available ad libitum.  Each 
animal was allocated a unique identification number by implantation of a 
transponder (Microchip Identification Devices - Fingerprint UK). 
The PC·3M·luc cells were maintained in vitro in RPMI culture medium (Sigma, UK) 
containing 10% (v/v) heat inactivated foetal bovine serum (Sigma, Poole, UK) & 2 
mM L·glutamine (Sigma, UK) at 37 °C in 5% CO2 and humidified conditions and 
selected once a week with Zeocin (0.2mg/ml). Cells from sub-confluent monolayers 
were harvested with 0.025% EDTA, washed in culture medium and counted. On day 
of initiation cells were harvested from semi-confluent monolayers with 0.025% 
EDTA, washed twice in the culture medium and counted. Cells with viability of 
>90% were re-suspended, for in vivo administration, in sterile phosphate buffered 
saline, pH 7.4 (PBS) at 5x107 cells/ml. 
Tumours for the orthotopic xenograft efficacy study were surgically initiated in the 
prostate of 80 male MF-1 nude mice in 3 batches over 3 days (1 batch per day) with 
the middle day being designated as day 0.  Mice were imaged on either day 6 or day 
7 prior to dosing in order to obtain bioluminescent (BLI) photon counts for 
randomisation and assignment to treatment groups.  In order to maintain social 
groups, mice were randomised on a per cage basis.  Mice that had very low or no BLI 
signal were excluded from the randomisation cohort as were mice with 
complications arising from surgery or those with extensive fighting injuries. 
Mice were dosed orally, twice daily from day 7, with the exception of imaging days 
when the morning dose was not given to allow for the imaging anaesthetic and a 
period of unconsciousness.  The positive control, docetaxel was dosed twice weekly 
intravenously.  VAL401 and risperidone dosing was initiated under an escalation 
schedule such that intended doses were reached by Day 14 according to the groups 
in the schedule below: 
Vehicle Group Days 7 – 42 Vehicle 
Risperidone Group Days 7 – 10 Risperidone 0.25 mg/kg 
Days 11 – 14  Risperidone 0.5 mg/kg 
Days 12 – 42  Risperidone 1 mg/kg 
Rumenic Acid Group Days 7 – 10  Rumenic Acid 0.17 mg/kg 
Days 11 – 14  Rumenic Acid 0.35 mg/kg 
Days 12 – 42 Rumenic Acid 0.68 mg/kg 
VAL401 low dose Group Days 7 – 10  VAL401 0.25 mg/kg 
Days 11 – 42  VAL401 0.5 mg/kg 
VAL401 high dose Group Days 7 – 10  VAL401 0.25 mg/kg 
Days 11 – 14  VAL401 0.5 mg/kg 
Days 12 – 42  VAL401 1 mg/kg 
Positive control Group Twice weekly Days 7 - 42 5 mg/kg i.v. Docetaxel 
 
VAL401 concentrations are quoted with respect to the risperidone content, with the 
rumenic acid being equimolar.  Risperidone was made to a stock of 10 mM and 
rumenic acid to a stock of 100 mM in ethanol.  These ethanol solutions were diluted 
into water to achieve concentrations such that for 0.25 mg/kg dosing the mice 
received 5ml/kg, for 0.5 mg/kg 10 ml/kg and for 1 mg/kg 10 ml/kg based on 
risperidone concentrations.  The vehicle group was dosed with a comparable 
volume of diluted ethanol solution. 
 
Mouse body weights were monitored for the duration of the study.  Generally, body 
weight was well maintained and increased over the duration of the study.  Non-
surviving mice were terminated according to home office regulations dictated by 
size of tumour. 
When humane endpoints, associated termination days and BLI values (1x1010 
photons/s) were used to conduct a surrogate endpoint survival analysis, median 
survival times (t1/2) were calculated to be 34 days for the vehicle treated group, and 
40 days for both the single agent risperidone and rumenic acid groups.  Due to the 
high proportion of surviving mice in the VAL401 group and the docetaxel positive 
control group, median survival times could not be calculated.  No premature 
terminations were carried out in the docetaxel treated group demonstrating success 
of the experimental conditions. 
 
3. Results 
Using the method we described previously [9] we immobilized chlorpromazine 1 in 
the wells of a Magic Tag® plate. Our method ensures that non-specific binding of 
proteins from the library is minimized, by using “protein resistant” oligo(ethylene 
glycol) groups and also that the bioactive molecule is presented to the library in 
numerous different orientations, thus maximizing the number of specific interactions 
with the library. 
The immobilized chlorpromazine 1 was exposed to the D. melanogaster phage-
displayed library of polypeptides in three rounds of biopanning. After all three 
rounds, phage that did not bind were removed by washing and the remaining, bound 
phage were amplified by re-infection of E. coli. After the final amplification step, 46 
significant plaque forming units were selected and the oligonucleotide sequences 
were obtained. Elimination of 11 clones that also occurred in the negative control 
wells (no drug added) left 35 clones of interest. These were submitted to a selective 
elution experiment, as we have described previously [6, 7] with a solution of free 
chlorpromazine. Significant elution in this experiment should indicate that a clone 
binds to unmodified drug as well as to a surface-modified analogue. Eight clones were 
judged to merit further study on this basis. 
Broadly in accordance with the extent of homology between humans and our chosen 
model D. melanogaster, discussed above, six of the eight clones had DNA inserts that 
corresponded to sections of orthologous human genes, of which one had previously 
been proposed as a therapeutic “target”. 17--Hydroxysteroid dehydrogenase 10 
(17HSD10, also known as ABAD, ERAB, Type II HADH, SCHAD etc.) is an intracellular 
binding partner for Amyloid -Peptide (A) and Kissinger et al. suggested inhibiting 
17HSD10 as a new approach to treating of Alzheimer’s Disease [13]. Additionally, 
17HSD10’s function in dihydrotestosterone synthesis led some authors to propose it 
as a prostate cancer target [15]. The enzyme is highly expressed in prostate cancer 
bone metastases, as compared with non-malignant and primary tumor tissues [16]. 
Recently, it has become apparent that 17HSD10 is overexpressed in many cancerous 
cells, particularly those of adenocarcinoma types [17], with the enzyme’s 
multifunctional nature contributing more broadly to the stabilisation of cancer cells 
[18]. 
To test whether antipsychotic drugs such as chlorpromazine would interact with 
normally expressed human 17HSD10 in vitro, we studied their effects on the 
recombinant 17HSD10 catalyzed oxidation reaction of estradiol and corresponding 
reduction of (acetylaceto) coenzyme A, using literature procedures [13, 14]. As well 
as chlorpromazine 1, we investigated two further antipsychotic drugs, clozapine 2 
and risperidone 3 that share a pharmacophore (Fig. 1). All three drugs 1, 2 and 3 
might be expected to exhibit similar polypharmacology, potentially including an 
association with 17HSD10. Clomipramine 4 was also included as a pharmacologically 
distinct antidepressant that, nevertheless, contains the same pharmacophoric 
element as chlorpromazine, clozapine and risperidone. The antihistamine 
diphenhydramine has neither the polycyclic structure of drugs 1 to 3 nor their 
pharmacological profile and was not expected to inhibit 17HSD10. 
 Drug type Oxidation rate / 
M min-1 
Reduction rate / 
M min-1 
No drug  8.4 8.8 
Chlorpromazine Antipsychotic 7.7 7.2 
Clozapine Antipsychotic 4.8 7.5 
Risperidone Antipsychotic 1.0 3.3 
Clomipramine Antidepressant 2.3 7.5 
Diphenhydrazine Antihistamine 8.0 8.3 
 
Figure 2. Inhibition by chlorpromazine and related drugs of reactions catalyzed by 17HSD10.  
Oxidation and reduction were studied using estradiol and (acetoacetyl) Coenzyme A substrates, 
respectively [13, 14]. Reaction progress was monitored by following the NAD absorbance at 340 nm. 
 
After initiation of the oxidation reaction by addition of estradiol, chlorpromazine, like 
the sedative diphenhydramine, was shown to have virtually no effect on the 
17HSD10-catalyzed dehydrogenation of estradiol. The other drugs tested showed 
higher levels of inhibition (Fig. 2). In the reduction reaction, chlorpromazine, 
clomipramine and diphenhydramine were shown to have little inhibitory effect on 
the 17HSD10-catalyzed hydrogenation of acetoacetyl coenzyme A. Clozapine and 
risperidone showed some inhibition (Fig. 2). To better understand why risperidone 
3 was the best inhibitor of 17HSD10 in both the oxidation and reduction reactions, 
we undertook a computational study. The crystal structure of human 17HSD10 in the 
presence of a potent inhibitor 5 has been disclosed [13], allowing us to attempt in 
silico docking studies. Docking of risperidone 3, AG18051 5, known inhibitor RM-532-
46 6 [15], and the NAD co-factor in 17HSD10, both in the presence and absence of 
water and the NAD co-factor respectively, was performed using AutoDock 4.2 [19, 20] 
and Glide docking software [21, 22]. After analysis of the resulting substrate-enzyme 
models (see the Supporting Information), the different docking poses, calculated 
using Glide and AutoDock 4.2 respectively, were scored and compared (Table 1, 
Supporting Information). 
 
Figure 3. Known inhibitors of 17HSD10 ASG18051 5 [13] and RM-532-46 6 [15]. 
 
Risperidone was predicted to bind best when there was no NAD co-factor present, 
which implies a competitive binding mode. This is a similar mode of binding to that 
predicted and observed for RM-532-46 6 [15] (Fig. 4). Unlike the case of the AG18051 
inhibitor, risperidone is unable to form a covalent interaction with the NAD co-factor 
which may therefore favour the predicted competitive mode of binding [13].  
     
Figure 4. Predicted binding of risperidone to 17-HSD10: (a) overlay of risperidone (cyan), RM-532-46 
(green) and NAD co-factor (orange), modelled in the active site of 17-HSD10 (PDB-ID: 1U7T); and (b) 
overlay of risperidone docked with Glide (cyan) and AutoDock (pink).  
 
To further investigate the binding of risperidone, chlorpromazine, clozapine and 
clomipramine to 17HSD10, we performed additional in silico docking studies. 
Docking of each substrate into the crystal structure of 17HSD10 (PDB-ID: 1U7T) in 
the absence of the NAD co-factor was performed using AutoDock 4.2 and Glide 
docking software respectively. Following analysis, each substrate-enzyme model (see 
the Supporting Information) was scored using Glide and AutoDock 4.2 (Table 2, 
Supporting Information). The highest-ranking substrate in terms of both the Glide 
and AutoDock scores is risperidone. 
 The sequence of our isolated clone includes most of the amino acids in close contact 
with the bound inhibitor 5 in the crystal [13]. The key tyrosine 168 and glutamine 
165 residues are both present in our analogue, as are the flanking alanines 95 and 97. 
Leucines 205, 206 and 209, which have been shown by Kissinger et al. to be in the 
active site [13], lie beyond the phage-displayed polypeptide sequence in our 
experiment. 
Given the literature observations on the importance of 17HSD10 expression in both 
Alzheimer’s disease and in prostate cancer, the finding that risperidone may be a 
competent inhibitor of the enzyme presents two drug reprofiling opportunities. Given 
the interest in reprofiling for oncology discussed above, we proceeded with the 
formulation of a risperidone-based drug for prostate cancer. We were aware of a 
significant literature summarized recently by Polavarapu et al. that suggests that 
polyunsaturated fatty acids, in particular in combination with certain other drugs, 
could potentially have anti-cancer activity [23]. Following both scientific (data not 
shown) and commercial evaluation, we designed VAL401 [24], a formulation of 
risperidone in rumenic acid. Rumenic acid, or 9-cis 11-trans linoleic acid is an 
important naturally occurring conjugated linoleic acid (CLA) found in particular in 
cow’s milk [25].   
 
 Figure 5. Effects of risperidone, rumenic acid and the VAL 401 formulation on prostate cancer cells 
and xenografts: (a) survival of PC3 prostate cancer cells at varying dose after 96 hours continuous 
treatment; and (b) survival of mice with PC3 orthotopic prostate cancer xenografts after daily oral 
treatment. 
 
VAL401 was tested in vitro against the PC3 prostate cancer cell line, which originates 
from bone cancer metastases. The experiment measured the number of cells still 
viable after 96 hours treatment using a total cell count assay which lyses the 
remaining cells and measures the level of lactate dehydrogenase (LDH) produced 
(Promega Cytox96 non-radioactive cytotoxicity assay). The percentage cell count was 
calculated by normalizing untreated cells as 100% growth and wells containing as 
0%.  The mean of the four replicate wells was calculated, and the standard error used 
to produce the error bars.  While risperidone alone was seen to have some activity 
against PC3 cells, rumenic acid alone had no effect at this level of dosing (Fig. 5a).  The 
formulation of risperidone in rumenic acid (VAL401) was most effective in slowing 
PC3 cell growth in this experiment. 
Finally, VAL401 was administered in vivo to mice implanted with PC3 prostate 
cancer xenografts.  The survival of mice during this experiment is displayed 
according to group (Fig. 5b). The VAL401 low dose group shows 70% survival, 
whereas risperidone and rumenic acid on their own offered no survival benefit after 
40 days, and the docetaxel positive control (administered intravenously) 
demonstrates the overall success of the experiment.  
 
4. Discussion 
Herein we have demonstrated the power of the Magic Tag® chemical genomics tool 
in a drug reprofiling context. Magic Tag® was successful in immobilizing an 
antipsychotic drug in a manner that allowed effective screening against a T7 phage 
displayed library. The use of D. melanogaster as a whole genome model uncovered a 
range of interesting interactions of potential relevance in humans, including 
apparent binding of the drug to a portion of D. melanogaster scully, an ortholog of 
human 17HSD10. Enzyme inhibition studies coupled with computational modelling 
indicated that, of the antipsychotic and related drugs in our study, risperidone was 
the best inhibitor of full length human 17HSD10 in vitro. Formulation of risperidone 
with rumenic acid created a new drug VAL401. VAL401 reduced activity of PC3 
prostate cancer cells in vitro and prolonged the lifetime of mice with PC3 prostate 
cancer xenografts in vivo. VAL401 is expected to proceed to clinical trials as a 
reprofiled drug for prostate cancer and other adenocarcinomas. 
The relationship between risperidone and NAD+ proposed here may have broader 
significance. Increasingly, the role of NAD+ in controlling both energy and signalling 
is being studied in relation to cancer cell proliferation [26]. For example, 
determination of [NAD+]/[NADH] ratios showed marked differences between 
prostate and breast cancer cells [27]. Effects on NAD+ levels may also explain further 
aspects of the broad pharmacological profile of risperidone [27]. 
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